Tag: non small cell lung cancer

April 16, 2018

BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas

BeiGene (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of...
April 16, 2018

G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer

G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has initiated a Phase 1b/2 clinical trial assessing G1T38,...
April 12, 2018

Illumina and Loxo Oncology Form Collaboration, Share Prices Increase

Illumina and Loxo have teamed up to develop and commercialize a multi-gene panel for broad tumor profiling for cancer indications.
April 3, 2018

BriaCell’s Lead Product Candidate Mechanism of Action Described in a Major Immunology Journal

BriaCell Therapeutics Corp. ("BriaCell") (TSXV:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to...
March 27, 2018

BriaCell Completes Previously Announced Oversubscribed Non-Brokered Private Placement and Concurrent Investment With Leading U.S. Biotech Funds

BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology,...
March 19, 2018

What is Oncology Investing?

What is oncology investing? This sector can be intimidating for investors first getting into the space — here's a brief breakdown...
March 16, 2018

Checkpoint Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results

Checkpoint Therapeutics (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients...